TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03737643

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab by intravenous infusion. In tBRCAm cohort bevacizumab is optional according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab by intravenous infusion. In tBRCAm cohort bevacizumab is optional according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab by intravenous infusion. In tBRCAm cohort bevacizumab is optional according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab by intravenous infusion. In tBRCAm cohort bevacizumab is optional according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab by intravenous infusion
Study: NCT01129960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (BIA 2-093)
Description: Tablets will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (BIA 2-093)
Description: Tablets will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (BIA 2-093)
Description: Tablets will be used.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets will be used.
Study: NCT03737643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo olaparib
Description: Placebo tablets to match olaparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo olaparib
Description: Placebo tablets to match olaparib
Study: NCT00892762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost APS 40 micrograms/ml eye drop solution
Description: non-BAK (benzalkonium chloride) medication
Study: NCT03737643

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab placebo
Description: Matching placebo for intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin+Paclitaxel
Description: Standard of care chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin+Paclitaxel
Description: Standard of care chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin+Paclitaxel
Description: Standard of care chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin+Paclitaxel
Description: Standard of care chemotherapy
Study: NCT03324646

Intervention type: DRUG
Intervention: [11C]PS13
Description: A novel PET ligand to selectively image COX-1
Study: NCT02625480

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brexucabtagene Autoleucel (KTE-X19)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously
Study: NCT03233399

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham TMS3 stimulation
Description: half of the subjects will receive sham stimulation first

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham TMS3 stimulation
Description: half of the subjects will receive sham stimulation first

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS of left or right angular gyrus (AG) or frontal cortex (FC)
Description: Half of the subjects will receive active stimulation first; A subject may receive either TMS or tDCS stimulation, but not both, over the course of the sub-study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS of left or right angular gyrus (AG) or frontal cortex (FC)
Description: Half of the subjects will receive active stimulation first; A subject may receive either TMS or tDCS stimulation, but not both, over the course of the sub-study.
Study: NCT00892762

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost 50 micrograms/ml eye drop solution
Description: BAK-preserved medication
Study: NCT02625480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously
Study: NCT03233399

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal tDCS of left or right AG or FC
Description: Half of the subjects will receive active stimulation first; A subject may receive either TMS or tDCS stimulation, but not both, over the course of the sub-study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal tDCS of left or right AG or FC
Description: Half of the subjects will receive active stimulation first; A subject may receive either TMS or tDCS stimulation, but not both, over the course of the sub-study.
Study: NCT00223145

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy 70 Gy
Description: Radiotherapy to the prostate
Study: NCT04231357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: platelet rich plasma prepared from peripheral blood using single spin centrifugation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich plasma
Description: platelet rich plasma prepared from peripheral blood using single spin centrifugation
Study: NCT00748397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixture MicroThread (Micro-Macro)
Description: Fixture MicroThread (Micro-Macro) Ø 3.5 and 4.0 mm in lengths of 9, 11, 13, 15 and 17 mm.
Study: NCT01663818

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tack-It Endovascular Stapler
Study: NCT02521753

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Intervention also includes weight reduction diet and exercise therapy

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium
Description: Intervention also includes weight reduction diet and exercise therapy

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PUFA
Description: Intervention also includes weight reduction diet and exercise therapy
Study: NCT01032954

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin
Description: Drug: Botulinum toxin~Indications for eligibility and total doses that will be applied in each part of the face, at visit 1:~Upper face:~* Crow's feet wrinkles - 70 units~* Glabella - 50 units~* Forehead - 40 units~Mid face:~* Lower eyelid - 5 units~* Nasal wrinkles - 20 units~* Malar wrinkles - 10 units~Lower face:~* Peri-oral wrinkles - 15 units~* Asymmetric smile or gummy smile - 5 units~* Cellulitic chin - 20 units~* Marionette lines - 25 U According to the patients needs, the doses can vary ±10% in terms of the amount of units that will be injected.~Patients will be allocated in each group and receive the doses described above at visit 1. At visit 2, all the patients will receive a touch-up of a standard dose of 25 U, distributed on the treated areas according patient's needs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin
Description: Drug: Botulinum toxin~Indications for eligibility and total doses that will be applied in each part of the face, at visit 1:~Upper face:~* Crow's feet wrinkles - 70 units~* Glabella - 50 units~* Forehead - 40 units~Mid face:~* Lower eyelid - 5 units~* Nasal wrinkles - 20 units~* Malar wrinkles - 10 units~Lower face:~* Peri-oral wrinkles - 15 units~* Asymmetric smile or gummy smile - 5 units~* Cellulitic chin - 20 units~* Marionette lines - 25 U According to the patients needs, the doses can vary ±10% in terms of the amount of units that will be injected.~Patients will be allocated in each group and receive the doses described above at visit 1. At visit 2, all the patients will receive a touch-up of a standard dose of 25 U, distributed on the treated areas according patient's needs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin
Description: Drug: Botulinum toxin~Indications for eligibility and total doses that will be applied in each part of the face, at visit 1:~Upper face:~* Crow's feet wrinkles - 70 units~* Glabella - 50 units~* Forehead - 40 units~Mid face:~* Lower eyelid - 5 units~* Nasal wrinkles - 20 units~* Malar wrinkles - 10 units~Lower face:~* Peri-oral wrinkles - 15 units~* Asymmetric smile or gummy smile - 5 units~* Cellulitic chin - 20 units~* Marionette lines - 25 U According to the patients needs, the doses can vary ±10% in terms of the amount of units that will be injected.~Patients will be allocated in each group and receive the doses described above at visit 1. At visit 2, all the patients will receive a touch-up of a standard dose of 25 U, distributed on the treated areas according patient's needs.
Study: NCT04913168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Front Line Worker Pilot Project
Description: 13-month intervention targeting workplace policies and programs focused on changes to safety and ergonomics, job enrichment, and work intensity for front line food service workers practices,
Study: NCT00223145

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy 76 Gy
Description: Radiotherapy to the prostate

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy 76 Gy
Description: Radiotherapy to the prostate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen blockade
Description: Duration : 6 months
Study: NCT03551288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUVN-911
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUVN-911
Description: Tablet
Study: NCT01184079

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: quadrivalent human papillomavirus vaccine
Description: 0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 12 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: quadrivalent human papillomavirus vaccine
Description: 0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 6 months
Study: NCT01028287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACTH
Description: Patients with nephrotic range proteinuria randomized to this group will receive 32 units ACTHargel sub-cutaneously every day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACTH
Description: Patients with nephrotic range proteinuria randomized to this group will receive 32 units ACTHargel sub-cutaneously every day.
Study: NCT04614415

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autocrosslinked Hyaluronic aid
Description: IAL-SYSTEM ACP gel is an auto-cross-linked HA derivative in the form of highly viscous gel. In this direct formation of ester linkages no foreign substances are introduced into the molecule, thus catabolism of ACP leads only to HA

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo consists in an isotonic saline solution (NaCl 0.9%)
Study: NCT04603157

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hybrid Exercise Training
Description: Personalized exercise program completing at least 3 aerobic exercise sessions a week and receive eight supervised training sessions over the 3-months
Study: NCT02613182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEOD001
Description: NEOD001
Study: NCT01505582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Three times daily inspiratory muscle training (2x30 breaths) at an intensity of 60% Pi,max

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham inspiratory muscle training
Description: Three times daily inspiratory muscle training (2x30 breaths) at an intensity of 10% Pi,max
Study: NCT03349086

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voice Exercise
Description: Voice exercise will consist of sustained pitches and pitch glides on a variety of different vocal facilitators.
Study: NCT03495349

Intervention type: OTHER
Intervention: safety and effectiveness of the usual treatments of diabetic foot infections
Description: clinical and biological follow-up necessary to assess the safety and effectiveness of the medical treatments, MOS-SF survey (36-Item Short Form Survey) to study the quality of life.
Study: NCT03340207

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pneumaglide
Description: The device is designed to facilitate intubation and reduce the time to intubation. It works with traditional glidescope to make the process of intubation easier. In this study patients scheduled for surgery and intubation, will be randomized to two groups. The intervention group will be intubated with the help of the pneumaglide. Yet, the other group will receive standard intubation. We aim to evaluate the efficacy of the Pneumaglide to improve the ease of intubation in unskilled clinicians and skilled clinicians during difficult and routine intubations
Study: NCT04697082

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Open surgery
Description: Each patient entered the operating room, and after the administration of general anaesthesia, the patient was placed in the prone position. Then, the buttocks were stretched to the lateral sides using adhesive bands to remove the disease area. The sacrococcygeal region was cleaned and disinfected with 10% povidone iodine. After covering the area around the region, the sinus tract was examined by using a thin-steel cane. The length and wealth of the cavity were noted. Then, the sinus tract was removed. The depth of the cavity was noted. Then, 50 cc of 0.9% saline solution (SS) was taken into a syringe and applied to the cavity until it filled the whole space, allowing the cavity volume to be measured accurately. The measurement was performed by subtracting the remaining saline-solution volume in the syringe from the whole syringe volume, which was 50 cc.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open surgery
Description: Each patient entered the operating room, and after the administration of general anaesthesia, the patient was placed in the prone position. Then, the buttocks were stretched to the lateral sides using adhesive bands to remove the disease area. The sacrococcygeal region was cleaned and disinfected with 10% povidone iodine. After covering the area around the region, the sinus tract was examined by using a thin-steel cane. The length and wealth of the cavity were noted. Then, the sinus tract was removed. The depth of the cavity was noted. Then, 50 cc of 0.9% saline solution (SS) was taken into a syringe and applied to the cavity until it filled the whole space, allowing the cavity volume to be measured accurately. The measurement was performed by subtracting the remaining saline-solution volume in the syringe from the whole syringe volume, which was 50 cc.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimal invasive surgery
Description: In the operating room, after the patient was placed in the prone position, the region was removed by stretching the buttocks with adhesive bands and cleaning the area with 10% povidone iodine. The largest pit was excised, and hairs in the cavity were removed with forceps. Then, the whole cavity was curetted meticulously and irrigated with SS. After haemostasis, the cavity volume was measured

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma administration
Description: Platelet rich plasma (PRP) was administered by filling the whole space from the lateral side of the cavity. After the first implementation of PRP, the second one was applied at 48 hours. Until that time, the dressing was not uncovered. PRP was applied on the 3rd, 4th and 5th days postoperatively.
Study: NCT00223145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen blockade
Description: Duration : 6 months
Study: NCT03595124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT03596385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta blocker
Description: long-term maintenance beta-blocker therapy
Study: NCT03742258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spleen Tyrosine Kinase Inhibitor TAK-659
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spleen Tyrosine Kinase Inhibitor TAK-659
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spleen Tyrosine Kinase Inhibitor TAK-659
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT03013101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: humanized anti-PD-1 monoclonal antibody toripalimab
Description: humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
Study: NCT00791453

Intervention type: BEHAVIORAL
Intervention: Education
Description: Patients will receive literacy appropriate health information.
Study: NCT03647150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin
Description: At enrollment the child will receive a 1 week course of amoxicillin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready-to-use therapeutic food (RUTF)
Description: 1 sachet RUTF per day (508 calories) till child MUAC is greater than 12.4 cm or 12 weeks have elapsed

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mother Care group
Description: Nutrition education via mother care groups lead by a respected elder in the local community

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mother Care group
Description: Nutrition education via mother care groups lead by a respected elder in the local community
Study: NCT03643315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and Meal (EX)
Description: 30 minute acute bout of high intensity intermittent exercise followed by ad-libitum meal

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No-Exercise and Meal (NEX)
Description: 30 minute non-exercise period where participants will be watching a video/movie followed by ad-libitum meal
Study: NCT00294645

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transtelephonic monitoring (TTM)
Description: TTM conducted at 2 month intervals. For patients with dual-chamber pacemakers, an in-office visit was required at 6 months (rather than TTM transmission for patients with single-chamber pacemakers). Follow-up frequency established to mimic best case standard of care when utilizing TTM for follow-up. A 12-month in-office visit completed the follow-up period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic CareLink® Network
Description: Remote pacemaker interrogation conducted at 3 month intervals. Follow-up frequency established to mimic best case standard of care when utilizing implantable cardioverter defibrillator (ICD) remote interrogation for follow-up. A 12-month in-office visit completed the follow-up period.
Study: NCT02693054

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HALO
Description: Laser Treatment
Study: NCT01543399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tibolone
Description: Experimental group will use 2.5mg of tibolone for 30 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients of the placebo group will use placebo one a day for 30 days
Study: NCT01783314

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI of liver
Description: MRI of liver with intravenous gadoxetate disodium

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI of liver
Description: MRI of liver with intravenous gadoxetate disodium
Study: NCT00075114

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Bladder Health Class
Description: A two-hour bladder health class presented by two experts in urinary incontinence and followed by an individual follow-up teaching session with an incontinence nurse specialist.
Study: NCT01330628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Turbo Elite Laser and Turbo Tandem Laser Guide Catheters
Description: application of laser energy to remove blockage followed by standard balloon angioplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon angioplasty
Description: standard balloon catheters for PTA
Study: NCT04854525

Intervention type: RADIATION
Intervention: Pre reconstruction Radiotherapy
Description: Previous PMRT

Intervention type: RADIATION
Intervention: Pre reconstruction Radiotherapy
Description: Previous PMRT

Intervention type: RADIATION
Intervention: Pre reconstruction Radiotherapy
Description: Previous PMRT
Study: NCT01476319

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video
Description: The intervention group includes patients who obtain information about percutaneous cholecystostomy from a video will view at their bedside on a laptop.